<SEC-DOCUMENT>0001104659-20-076856.txt : 20200625
<SEC-HEADER>0001104659-20-076856.hdr.sgml : 20200625
<ACCEPTANCE-DATETIME>20200625160844
ACCESSION NUMBER:		0001104659-20-076856
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200625
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200625
DATE AS OF CHANGE:		20200625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEAP THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001509745
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				274412575
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37990
		FILM NUMBER:		20989349

	BUSINESS ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617 252 4343

	MAIL ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dekkun Corp
		DATE OF NAME CHANGE:	20110107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2023367-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED
STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(D)</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>June 25, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leap Therapeutics, Inc.</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-37990</B></FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-4412575</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR> of incorporation)</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt">(Commission<BR> File Number)</TD>
<TD STYLE="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt">(IRS Employer<BR> Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="2" STYLE="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="background-color: white"><B>47 Thorndike Street, Suite B1-1<BR> Cambridge, MA</B></FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; background-color: white"><B>02141</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 36%"><FONT STYLE="font-size: 0.1pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 15%"><FONT STYLE="font-size: 0.1pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 17%"><FONT STYLE="font-size: 0.1pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 0.1pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
        area code: <B>(617)&nbsp;714-0360</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address,
if changed since last report)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8&#45;K is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17&nbsp;CFR&nbsp;230.425).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a&#45;12
under the Exchange Act (17&nbsp;CFR&nbsp;240.14a&#45;12).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d&#45;2(b)
under the Exchange Act (17&nbsp;CFR 240.14d&#45;2(b)).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e&#45;4(c)
under the Exchange Act (17&nbsp;CFR 240.13e&#45;4(c)).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of each exchange on which <BR>
registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">LPTX</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nasdaq Global Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;8.01. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2020, the Company issued a
press release announcing the full exercise of the underwriters&rsquo; option to purchase additional shares in its previously disclosed
underwritten public offering. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial
Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 8%"><B>Exhibit<BR> Number</B>&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
<TD STYLE="text-align: center; border-bottom: Black 1pt solid; width: 90%"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="tm2023367d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="tm2023367d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release dated June 25, 2020.</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">LEAP THERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Dated: June 25, 2020</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Douglas E. Onsi</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Douglas E. Onsi</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2023367d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm2023367d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leap Therapeutics Announces Full Exercise
of Underwriters&rsquo; Option to Purchase Additional Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify"><B>Cambridge, MA &ndash; June
25, 2020</B> &ndash; Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology
therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the
underwriters&rsquo; option to purchase additional shares from Leap&rsquo;s previously announced public offering. After giving effect
to the full exercise of the option, the aggregate gross proceeds to Leap from this offering were approximately $51.75 million,
before deducting underwriting discounts and commissions and other offering expenses payable by Leap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">Piper Sandler &amp; Co. and Raymond
James &amp; Associates, Inc. acted as book-running managers for the offering. Robert W. Baird &amp; Co. Incorporated acted as the
lead manager. H.C. Wainwright &amp; Co. and Ladenburg Thalmann &amp; Co. Inc. acted as co-managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">The securities were offered
and sold pursuant to an effective shelf registration statement on Form S-3 (File No. 333-223419) that was previously filed by
Leap with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on March 2, 2018 and was declared effective by the SEC
on March 16, 2018. A preliminary prospectus supplement and the related prospectus has been filed with the SEC and will be available
for free on the SEC&rsquo;s website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus
relating to the offering, when available, may be obtained from: <FONT STYLE="background-color: white">Piper Sandler &amp; Co.,
800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email
at <U>prospectus@psc.com</U></FONT> or Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway,
St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at <U>prospectus@raymondjames.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">This press release shall not
constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Leap Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leap Therapeutics (Nasdaq:LPTX) is focused
on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal
antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric,
hepatobiliary, gynecologic, and prostate cancers. Leap has formed a partnership with BeiGene, Ltd. for the rights to develop DKN-01
in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com
or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via <U>https://investors.leaptx.com/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These
statements include statements relating to the offering, Leap&rsquo;s expectations with respect to the development and
advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential
for the receipt of future option exercise, milestones or royalty payments from BeiGene, and other future expectations, plans
and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of
the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could
cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited
to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and
other studies may be delayed, adversely affected, or impacted by COVID-19 related issues, the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our
product development activities and clinical trials; the uncertain clinical development process, including the risk that
clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our
ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other
risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap
Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December
31, 2019, as filed with the SEC on March 16, 2020 and as may be updated by Leap&rsquo;s Quarterly Reports on Form 10-Q and
the other reports we file from time to time with the SEC. Any forward-looking statements contained in this release speak only
as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Douglas E. Onsi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President &amp; Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leap Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">617-714-0360</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>donsi@leaptx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Heather Savelle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Argot Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">212-600-1902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>heather@argotpartners.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2023367d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2023367d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 1L# 2(  A$! Q$!_\0
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M>>I+'/\ .C4"^"& *D$'H13'GAC.'E13_M,!65I8-KJEY8*Q,* .@)SC./\
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M":V:JW]DFH6I@=BO.0P[&JB6NKDA'OHP@ZLJ?,1^5>;U/7V"Y_Y&*Q_ZYO\
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
